NOX Noxopharm Limited
—Mkt Cap: —P/E: —1d ago
Noxopharm Limited, a clinical-stage biotechnology company, engages in the development of therapies for chronic inflammation, autoimmune diseases, and cancer in the Pan-Pacific region. The company develops Sofra, a platfo…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value13.57M USD
Revenue (TTM)986.43K USD
Gross Profit-356.36K USD
Net Income (TTM)-2.47M USD
Revenue/Share0.0050 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU000000NOX9
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-5.75
EV/Revenue13.76
P/S10.76
P/B-4.17
EPS (TTM)-0.01
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin-36.13%
Oper. Margin702.33%
EBITDA Margin-239.47%
Profit Margin0.00%
ROE-65.11%
ROA-52.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.87M USD
CapEx (TTM)—
FCF Margin-123.91%
FCF Yield—
Net Debt2.96M USD
Net Debt/EBITDA-1.25
Balance Sheet
Debt/Equity—
Current Ratio0.34
Quick Ratio0.33
Book Value/Sh-0.01 AUD
Cash/Share0.0010 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.307.24M
Float207.08M
Insiders31.75%
Institutions0.00%
Technical
SMA 500.0720 AUD
SMA 2000.0741 AUD
Beta0.13
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)46.88K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—